Table 2.

Drug-related adverse events

All doses n = 152275 mg fed (RP2D) n = 74
Adverse eventAll gradesn (%)Grades 1–2n (%)Grades 3–4n (%)All gradesn (%)Grades 1–2n (%)Grades 3–4n (%)
Fatigue38 (25)33 (22)5 (3)16 (22)16 (22)
Diarrhea37 (24)29 (19)8 (5)16 (22)13 (18)3 (4)
Hypophosphatemia27 (18)14 (9)13 (9)12 (17)7 (10)5 (7)
Rash, maculopapular27 (18)16 (11)11 (7)12 (17)5 (7)7 (10)
Rash, nonmaculopapular26 (17)24 (16)2 (1)16 (21)15 (20)1 (1)
Nausea22 (15)22 (15)6 (8)6 (8)
Elevated ALT21 (14)9 (6)12 (8)12 (16)6 (8)6 (8)
Elevated AST20 (13)12 (8)8 (5)12 (16)8 (11)4 (5)
Muscle spasms19 (13)19 (13)5 (7)5 (7)
Decreased appetite17 (11)17 (11)8 (11)8 (11)
Vomiting16 (11)16 (11)6 (8)6 (8)
  • NOTE: The most common adverse events related to RXDX-105 therapy that were observed in more than 10% of all patients are listed. The frequency of these toxicities is shown for all 152 patients who were treated with RXDX-105 at any dose, and in 74 patients who were treated at the recommended phase II dose (RP2D) of 275 mg fed.

  • Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.